secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2023-10-27T23:59:59+00:00
Accession:  0001104659-23-112202
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 5.03, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar shareholders approve 10M share increase; Nasdaq OKs compliance plan with Feb 12 deadline
--------------------------------------------------------------------------------

- Shareholders approved amendment to increase authorized common stock from 160M to 170M shares at special meeting on Oct 25.
- Issuance proposal (conversion of Series E Preferred >19.99% of outstanding) approved with 3,318,009 votes for, 236,357 against.
- Nasdaq non-compliance with $2.5M stockholders' equity rule; plan approved; deadlines: Jan 4 warrant update, Feb 12 compliance evidence.
- Failure to demonstrate compliance by Q1 2024 filing may result in delisting; company cautions no assurance of regaining compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465923112202/0001104659-23-112202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465923112202/tm2329288d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-112202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer